This page shows the latest cemiplimab news and features for those working in and with pharma, biotech and healthcare.
Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) has been approved by the European Commission (EC) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease
Regeneron’s PD-1 inhibitor Libtayo (cemiplimab-rwlc) has been approved by the US Food and Drug Administration (FDA) in combination with platinum-based chemotherapy as a first-line treatment for ... Even with these diverse disease presentations,
Libtayo (cemiplimab) in advanced melanoma.
Regeneron has announced positive data from a phase 2 trial for an investigational regimen of PD-1 inhibitor Libtayo (cemiplimab) as a neoadjuvant monotherapy in stage two to four resectable cutaneous
The National Institute for Health and Care Excellence (NICE) has recommended Sanofi and Regeneron’s Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC). ... The multicentre, non-randomised
In March, Sanofi and Regeneron revealed positive data for their PD-1 inhibitor Libtayo (cemiplimab) in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.
More from news
Approximately 3 fully matching, plus 30 partially matching documents found.
Regeneron and its long-standing partners Sanofi look set to gain FDA approval for their PD-1 immunotherapy contender, cemiplimab in October, while Bluebird is poised to file its
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...